glycopyrronium bromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4302	596-51-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sialanar NVA237 Seebri Breezhaler glycopyrronium bromide copyrrolate gastrodyn glycopyrrolate robanul glycopyrronium glycopyrrolate bromide glycopyrronium tosilate glycopyrronium tosilate hydrate	Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine and acetylcholine induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect. Molecular weight: 318.44 Formula: C19H28NO3 CLOGP: 0.12 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 46.53 ALOGS: -5.57 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

sialanar
NVA237
Seebri Breezhaler
glycopyrronium bromide
copyrrolate
gastrodyn
glycopyrrolate
robanul
glycopyrronium
glycopyrrolate bromide
glycopyrronium tosilate
glycopyrronium tosilate hydrate

Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine and acetylcholine induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect.

Molecular weight: 318.44
Formula: C19H28NO3
CLOGP: 0.12
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 46.53
ALOGS: -5.57
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	O
0.30	mg	P
3	mg	R
44	mcg	Inhal.powder

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	17 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.37 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.65 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.48 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company
Aug. 11, 1961	FDA	SHIONOGI INC
June 18, 2019	PMDA	AstraZeneca K.K.
Sept. 28, 2012	EMA	Novartis Europharm Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	518.72	16.95	362	17223	127199	63344238
Wheezing	493.89	16.95	315	17270	95280	63376157
Total lung capacity increased	316.80	16.95	82	17503	2228	63469209
Obstructive airways disorder	307.21	16.95	138	17447	20561	63450876
Bronchiectasis	228.02	16.95	104	17481	16038	63455399
Cough	224.62	16.95	336	17249	292407	63179030
Dyspnoea	219.76	16.95	530	17055	660783	62810654
Asthma-chronic obstructive pulmonary disease overlap syndrome	215.32	16.95	59	17526	2002	63469435
Forced expiratory volume decreased	210.50	16.95	71	17514	4897	63466540
Nasal congestion	202.33	16.95	158	17427	65502	63405935
Nasal polyps	189.46	16.95	69	17516	5970	63465467
Blood immunoglobulin E increased	187.03	16.95	61	17524	3788	63467649
Chronic obstructive pulmonary disease	170.02	16.95	140	17445	62546	63408891
Malignant mediastinal neoplasm	163.22	16.95	44	17541	1402	63470035
Sputum discoloured	148.71	16.95	78	17507	16269	63455168
Sarcoidosis	140.16	16.95	58	17527	7064	63464373
Productive cough	132.67	16.95	122	17463	63086	63408351
Respiration abnormal	132.20	16.95	54	17531	6363	63465074
Full blood count abnormal	130.72	16.95	91	17494	31626	63439811
Bronchial neoplasm	126.15	16.95	29	17556	471	63470966
Sleep disorder due to a general medical condition	124.85	16.95	63	17522	12125	63459312
Lung neoplasm malignant	124.76	16.95	74	17511	19559	63451878
Bronchial haemorrhage	121.27	16.95	29	17556	563	63470874
Sleep apnoea syndrome	116.36	16.95	82	17503	29051	63442386
Rhinitis allergic	115.41	16.95	59	17526	11668	63459769
Nasal turbinate hypertrophy	113.96	16.95	29	17556	734	63470703
Bronchial disorder	107.74	16.95	31	17554	1259	63470178
Endometrial ablation	107.24	16.95	29	17556	935	63470502
Hyper IgE syndrome	104.56	16.95	25	17560	485	63470952
Rhinorrhoea	102.93	16.95	108	17477	65469	63405968
Cardiac murmur	100.77	16.95	58	17527	14494	63456943
Chest discomfort	96.77	16.95	135	17450	109834	63361603
Glaucoma	96.56	16.95	62	17523	18843	63452594
Restrictive pulmonary disease	93.52	16.95	30	17555	1765	63469672
Heart sounds	87.96	16.95	25	17560	971	63470466
Rhonchi	86.66	16.95	31	17554	2545	63468892
Prolonged expiration	85.60	16.95	25	17560	1071	63470366
Humidity intolerance	80.75	16.95	19	17566	343	63471094
Hypomania	77.62	16.95	37	17548	6293	63465144
Pain	77.07	16.95	56	17529	740572	62730865
Pneumonia	76.17	16.95	288	17297	456479	63014958
Peak expiratory flow rate decreased	75.05	16.95	20	17565	609	63470828
Jaundice cholestatic	72.50	16.95	37	17548	7287	63464150
Alopecia	71.23	16.95	6	17579	337530	63133907
Rhinitis	67.43	16.95	41	17544	11325	63460112
Secretion discharge	67.17	16.95	42	17543	12189	63459248
Schizophrenia	67.13	16.95	39	17546	9913	63461524
Lower respiratory tract infection	65.25	16.95	125	17460	132182	63339255
Breast cancer recurrent	64.53	16.95	29	17556	4312	63467125
Dyspnoea exertional	59.02	16.95	78	17507	60224	63411213
Granuloma	56.72	16.95	29	17556	5732	63465705
Infusion related reaction	55.76	16.95	3	17582	245518	63225919
Affective disorder	54.95	16.95	29	17556	6117	63465320
Therapeutic product effect incomplete	54.25	16.95	112	17473	124944	63346493
Gastrooesophageal reflux disease	54.24	16.95	96	17489	95543	63375894
Frustration tolerance decreased	54.18	16.95	30	17555	6958	63464479
Rales	53.62	16.95	37	17548	12660	63458777
Breath sounds abnormal	53.60	16.95	35	17550	10938	63460499
Depressive symptom	53.43	16.95	25	17560	4077	63467360
Arthropathy	52.91	16.95	3	17582	234789	63236648
Polycystic ovaries	51.38	16.95	25	17560	4446	63466991
Pulmonary function test decreased	51.24	16.95	24	17561	3923	63467514
Joint swelling	50.76	16.95	14	17571	327652	63143785
Drug intolerance	50.08	16.95	12	17573	308649	63162788
Rash	48.98	16.95	50	17535	560821	62910616
Forced vital capacity decreased	47.99	16.95	16	17569	1063	63470374
Appetite disorder	47.56	16.95	28	17557	7293	63464144
Lung diffusion test decreased	46.15	16.95	14	17571	684	63470753
Rheumatoid arthritis	42.91	16.95	9	17576	253810	63217627
Middle insomnia	42.32	16.95	32	17553	12611	63458826
Depression	42.25	16.95	135	17450	196357	63275080
Arthralgia	41.03	16.95	59	17526	569651	62901786
Treatment failure	40.71	16.95	4	17581	199039	63272398
Dyslipidaemia	39.62	16.95	25	17560	7368	63464069
Therapeutic product effect decreased	39.20	16.95	4	17581	193183	63278254
Oxygen saturation decreased	39.17	16.95	80	17505	88505	63382932
Systemic lupus erythematosus	38.34	16.95	6	17579	208912	63262525
Choking	37.56	16.95	27	17558	9852	63461585
Nail dystrophy	36.78	16.95	13	17572	1030	63470407
Diarrhoea	36.66	16.95	91	17494	715275	62756162
Sinus tachycardia	36.32	16.95	39	17546	24229	63447208
Psychotic disorder	36.18	16.95	40	17545	25672	63445765
Pulmonary thrombosis	35.90	16.95	25	17560	8677	63462760
Restless legs syndrome	35.44	16.95	34	17551	18497	63452940
Synovitis	35.15	16.95	5	17580	186913	63284524
Seizure	35.00	16.95	98	17487	132536	63338901
Body temperature abnormal	34.75	16.95	15	17570	2026	63469411
Influenza	34.45	16.95	86	17499	108636	63362801
Sneezing	34.04	16.95	33	17552	18185	63453252
Pulmonary congestion	33.39	16.95	32	17553	17386	63454051
Angioplasty	33.12	16.95	13	17572	1379	63470058
Nasal inflammation	32.78	16.95	10	17575	498	63470939
Blood test abnormal	32.42	16.95	30	17555	15599	63455838
Pulmonary oedema	32.28	16.95	56	17529	54817	63416620
Bronchospasm paradoxical	31.90	16.95	7	17578	91	63471346
Blood bilirubin increased	31.73	16.95	45	17540	37095	63434342
Brain injury	30.86	16.95	21	17564	7022	63464415
Coronary artery disease	30.32	16.95	41	17544	32336	63439101
Respiratory disorder	29.98	16.95	45	17540	39037	63432400
Staphylococcal scalded skin syndrome	29.87	16.95	7	17578	124	63471313
Abdominal discomfort	29.82	16.95	27	17558	320858	63150579
Axillary pain	28.69	16.95	13	17572	1970	63469467
Blood pressure systolic increased	27.39	16.95	48	17537	47349	63424088
Ankle fracture	27.26	16.95	29	17556	17826	63453611
Abscess	27.10	16.95	28	17557	16640	63454797
Tachycardia	27.04	16.95	83	17502	118073	63353364
Granulomatosis with polyangiitis	27.04	16.95	13	17572	2252	63469185
Swelling	27.01	16.95	22	17563	275356	63196081
Increased bronchial secretion	26.89	16.95	12	17573	1754	63469683
Vulvovaginal candidiasis	25.63	16.95	14	17571	3161	63468276
Staphylococcus test positive	25.56	16.95	15	17570	3881	63467556
Paranoia	25.36	16.95	23	17562	11656	63459781
Cholelithiasis	24.76	16.95	44	17541	43881	63427556
Drug ineffective	24.75	16.95	179	17406	1044586	62426851
Hepatotoxicity	24.71	16.95	40	17545	37001	63434436
Peripheral vascular disorder	24.11	16.95	17	17568	6018	63465419
Fatigue	24.10	16.95	146	17439	887882	62583555
Dystonia	23.90	16.95	24	17561	13795	63457642
Anaphylactic reaction	23.85	16.95	55	17530	66045	63405392
Dysphonia	23.45	16.95	45	17540	47569	63423868
Stress cardiomyopathy	23.30	16.95	20	17565	9430	63462007
Catheter site haemorrhage	22.90	16.95	13	17572	3162	63468275
Nasopharyngitis	22.74	16.95	134	17451	254123	63217314
Blood disorder	22.36	16.95	17	17568	6754	63464683
Respiratory symptom	22.26	16.95	13	17572	3334	63468103
Muscle disorder	22.21	16.95	15	17570	4954	63466483
Bronchial obstruction	22.18	16.95	10	17575	1497	63469940
Flank pain	22.18	16.95	25	17560	16385	63455052
Apnoea	21.89	16.95	18	17567	8004	63463433
Crepitations	21.85	16.95	18	17567	8022	63463415
Appendicitis	21.48	16.95	18	17567	8211	63463226
Blister	21.12	16.95	5	17580	129809	63341628
Cerebral thrombosis	21.08	16.95	10	17575	1681	63469756
Laryngospasm	20.77	16.95	12	17573	3016	63468421
Infective exacerbation of chronic obstructive airways disease	20.62	16.95	9	17576	1248	63470189
Bronchial wall thickening	19.10	16.95	9	17576	1490	63469947
Laryngitis fungal	19.09	16.95	5	17580	142	63471295
Opisthotonus	18.75	16.95	6	17579	350	63471087
Impaired healing	18.68	16.95	3	17582	102539	63368898
Oropharyngitis fungal	18.60	16.95	4	17581	47	63471390
Arthritis	18.30	16.95	72	17513	115849	63355588
Respiratory acidosis	18.18	16.95	15	17570	6700	63464737
Discomfort	18.17	16.95	12	17573	167362	63304075
White blood cell count decreased	17.98	16.95	8	17577	139096	63332341
Eosinophilic pneumonia chronic	17.62	16.95	5	17580	193	63471244
Respiratory failure	17.50	16.95	65	17520	101793	63369644
Loss of personal independence in daily activities	17.49	16.95	63	17522	97227	63374210
Seasonal allergy	17.33	16.95	25	17560	20925	63450512
Subretinal fluid	17.22	16.95	6	17579	456	63470981
Smoke sensitivity	17.17	16.95	6	17579	460	63470977
Neutropenia	17.12	16.95	14	17571	174991	63296446
Presbyopia	17.10	16.95	6	17579	465	63470972
Weight decreased	17.03	16.95	133	17452	276665	63194772
Atrioventricular dissociation	16.97	16.95	5	17580	221	63471216

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	193.58	16.59	134	10408	42522	34903867
Wheezing	180.70	16.59	127	10415	41275	34905114
Dyspnoea	133.40	16.59	326	10216	376456	34569933
Productive cough	128.90	16.59	100	10442	37713	34908676
Obstructive airways disorder	118.95	16.59	68	10474	15426	34930963
Rhinitis perennial	97.09	16.59	22	10520	305	34946084
Sleep disorder due to a general medical condition	91.04	16.59	40	10502	5181	34941208
Chronic obstructive pulmonary disease	80.61	16.59	86	10456	48832	34897557
Cough	80.36	16.59	154	10388	149986	34796403
Sputum discoloured	78.55	16.59	41	10501	7771	34938618
Pulmonary function test abnormal	76.42	16.59	29	10513	2581	34943808
Chest discomfort	74.62	16.59	87	10455	54443	34891946
Adjustment disorder	72.86	16.59	23	10519	1178	34945211
Asthma-chronic obstructive pulmonary disease overlap syndrome	71.30	16.59	23	10519	1264	34945125
Forced expiratory volume decreased	70.66	16.59	29	10513	3174	34943215
Full blood count abnormal	64.92	16.59	50	10492	18618	34927771
Blood immunoglobulin E increased	62.87	16.59	25	10517	2521	34943868
Dyspnoea exertional	59.10	16.59	69	10473	43210	34903179
Serotonin syndrome	51.67	16.59	45	10497	19888	34926501
Loss of personal independence in daily activities	50.55	16.59	56	10486	33123	34913266
Bronchial hyperreactivity	50.07	16.59	19	10523	1690	34944699
Gastrooesophageal reflux disease	47.71	16.59	58	10484	37866	34908523
Angle closure glaucoma	44.56	16.59	15	10527	942	34945447
Therapeutic product effect incomplete	43.19	16.59	64	10478	50477	34895912
Breath sounds abnormal	41.83	16.59	26	10516	6855	34939534
Dyspnoea at rest	41.09	16.59	21	10521	3807	34942582
Respiratory disorder	37.36	16.59	37	10505	19227	34927162
Prolonged expiration	34.63	16.59	9	10533	227	34946162
Hypercholesterolaemia	31.62	16.59	24	10518	8738	34937651
Saliva altered	31.41	16.59	8	10534	186	34946203
Ischaemic cardiomyopathy	31.11	16.59	21	10521	6368	34940021
Umbilical hernia	29.26	16.59	18	10524	4659	34941730
Smoke sensitivity	28.58	16.59	7	10535	138	34946251
Infective exacerbation of chronic obstructive airways disease	28.49	16.59	13	10529	1838	34944551
Cardiorenal syndrome	28.48	16.59	10	10532	713	34945676
Sputum purulent	28.03	16.59	9	10533	487	34945902
Dyspnoea paroxysmal nocturnal	27.81	16.59	12	10530	1487	34944902
Salivary hypersecretion	27.55	16.59	22	10520	8622	34937767
Obesity	27.34	16.59	26	10516	12852	34933537
Hypoxia	26.33	16.59	54	10488	55041	34891348
Middle insomnia	25.36	16.59	19	10523	6783	34939606
Tachycardia	25.16	16.59	69	10473	84703	34861686
Discomfort	23.86	16.59	29	10513	18909	34927480
Pseudomonal sepsis	23.08	16.59	14	10528	3533	34942856
Precancerous condition	22.88	16.59	5	10537	58	34946331
Occupational exposure to air contaminants	22.84	16.59	6	10536	158	34946231
Accelerated idioventricular rhythm	22.63	16.59	6	10536	164	34946225
Physical deconditioning	22.36	16.59	10	10532	1349	34945040
Nasal polyps	21.96	16.59	12	10530	2491	34943898
Emphysema	21.70	16.59	20	10522	9505	34936884
Eosinophil count increased	21.50	16.59	19	10523	8553	34937836
Bradycardia	21.01	16.59	60	10482	75358	34871031
Hypoventilation	21.00	16.59	13	10529	3401	34942988
Forced vital capacity decreased	20.49	16.59	8	10534	768	34945621
Sneezing	20.34	16.59	15	10527	5227	34941162
Perfume sensitivity	19.93	16.59	5	10537	109	34946280
Off label use	19.78	16.59	63	10479	419461	34526928
Anxiety	19.41	16.59	70	10472	99358	34847031
Nasal congestion	19.39	16.59	29	10513	23028	34923361
Drug intolerance	19.19	16.59	50	10492	59520	34886869
Seasonal allergy	19.19	16.59	16	10526	6659	34939730
Appendicitis perforated	19.13	16.59	10	10532	1898	34944491
Eosinophilic granulomatosis with polyangiitis	18.75	16.59	10	10532	1977	34944412
Anaesthetic complication neurological	18.54	16.59	6	10536	333	34946056
Rhinorrhoea	18.41	16.59	30	10512	25638	34920751
Laryngospasm	18.25	16.59	9	10533	1512	34944877
Grunting	17.52	16.59	6	10536	397	34945992
Odynophagia	17.48	16.59	14	10528	5507	34940882
Toxicity to various agents	17.30	16.59	21	10521	200341	34746048

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma	644.45	15.45	449	25314	134646	79583979
Wheezing	575.59	15.45	396	25367	116268	79602357
Obstructive airways disorder	380.09	15.45	191	25572	31268	79687357
Total lung capacity increased	295.25	15.45	80	25683	2218	79716407
Dyspnoea	277.65	15.45	749	25014	856276	78862349
Cough	269.76	15.45	449	25314	366340	79352285
Asthma-chronic obstructive pulmonary disease overlap syndrome	255.56	15.45	77	25686	3144	79715481
Forced expiratory volume decreased	252.34	15.45	95	25668	7719	79710906
Productive cough	220.49	15.45	201	25562	88130	79630495
Blood immunoglobulin E increased	217.48	15.45	79	25684	5803	79712822
Chronic obstructive pulmonary disease	214.43	15.45	195	25568	85224	79633401
Sputum discoloured	208.16	15.45	113	25650	21630	79696995
Nasal congestion	204.47	15.45	181	25582	76371	79642254
Bronchiectasis	202.32	15.45	112	25651	22274	79696351
Full blood count abnormal	166.01	15.45	123	25640	40351	79678274
Nasal polyps	162.78	15.45	68	25695	7259	79711366
Malignant mediastinal neoplasm	152.88	15.45	43	25720	1372	79717253
Sleep disorder due to a general medical condition	141.66	15.45	76	25687	14201	79704424
Chest discomfort	136.25	15.45	194	25569	137850	79580775
Sarcoidosis	122.80	15.45	58	25705	8277	79710348
Bronchial neoplasm	121.24	15.45	29	25734	479	79718146
Rhinitis allergic	120.85	15.45	65	25698	12204	79706421
Respiration abnormal	117.23	15.45	55	25708	7733	79710892
Nasal turbinate hypertrophy	111.39	15.45	29	25734	686	79717939
Sleep apnoea syndrome	111.03	15.45	93	25670	36385	79682240
Rhinorrhoea	109.67	15.45	129	25634	75945	79642680
Prolonged expiration	107.82	15.45	32	25731	1239	79717386
Gastrooesophageal reflux disease	105.02	15.45	148	25615	104098	79614527
Endometrial ablation	105.01	15.45	29	25734	864	79717761
Dyspnoea exertional	100.41	15.45	132	25631	86941	79631684
Hyper IgE syndrome	97.93	15.45	25	25738	546	79718079
Glaucoma	94.62	15.45	66	25697	19695	79698930
Bronchial haemorrhage	93.81	15.45	29	25734	1291	79717334
Lung neoplasm malignant	93.26	15.45	75	25688	27717	79690908
Restrictive pulmonary disease	92.75	15.45	34	25729	2561	79716064
Breath sounds abnormal	92.38	15.45	60	25703	15924	79702701
Rhinitis perennial	88.59	15.45	21	25742	333	79718292
Bronchial disorder	86.70	15.45	32	25731	2457	79716168
Cardiac murmur	83.21	15.45	56	25707	15768	79702857
Heart sounds	80.54	15.45	24	25739	942	79717683
Rhonchi	78.20	15.45	34	25729	4002	79714623
Humidity intolerance	75.63	15.45	19	25744	388	79718237
Lower respiratory tract infection	75.01	15.45	143	25620	129077	79589548
Pain	67.44	15.45	77	25686	703725	79014900
Forced vital capacity decreased	66.63	15.45	24	25739	1719	79716906
Hypomania	66.10	15.45	37	25726	7507	79711118
Peak expiratory flow rate decreased	65.88	15.45	19	25744	664	79717961
Pneumonia	65.49	15.45	400	25363	659846	79058779
Pulmonary function test abnormal	64.64	15.45	30	25733	4114	79714511
Middle insomnia	61.77	15.45	47	25716	16022	79702603
Therapeutic product effect incomplete	60.25	15.45	138	25625	141507	79577118
Respiratory disorder	56.38	15.45	71	25692	44785	79673840
Secretion discharge	55.69	15.45	43	25720	14979	79703646
Pulmonary function test decreased	55.07	15.45	33	25730	7604	79711021
Rhinitis	54.05	15.45	42	25721	14765	79703860
Joint swelling	52.83	15.45	14	25749	288632	79429993
Jaundice cholestatic	52.41	15.45	37	25726	11247	79707378
Polycystic ovaries	51.71	15.45	25	25738	3754	79714871
Sneezing	49.44	15.45	45	25718	19638	79698987
Frustration tolerance decreased	47.92	15.45	30	25733	7472	79711153
Alopecia	46.78	15.45	9	25754	231346	79487279
Infusion related reaction	46.46	15.45	9	25754	230228	79488397
Rash	46.45	15.45	72	25691	578286	79140339
Tachycardia	45.03	15.45	143	25620	177625	79541000
Schizophrenia	44.17	15.45	38	25725	15402	79703223
Toxicity to various agents	43.78	15.45	43	25720	421497	79297128
Granuloma	42.75	15.45	29	25734	8268	79710357
Affective disorder	42.68	15.45	29	25734	8290	79710335
Lung diffusion test decreased	42.55	15.45	16	25747	1294	79717331
Seasonal allergy	42.17	15.45	38	25725	16368	79702257
Adjustment disorder	41.66	15.45	22	25741	3978	79714647
Choking	41.32	15.45	33	25730	12068	79706557
Bronchial hyperreactivity	41.26	15.45	20	25743	3020	79715605
Appetite disorder	39.76	15.45	27	25736	7712	79710913
Contraindicated product administered	39.45	15.45	3	25760	157535	79561090
Angle closure glaucoma	38.66	15.45	19	25744	2957	79715668
Rheumatoid arthritis	38.34	15.45	10	25753	208460	79510165
Treatment failure	38.13	15.45	5	25758	170481	79548144
Smoke sensitivity	37.39	15.45	12	25751	604	79718021
Depressive symptom	36.84	15.45	24	25739	6399	79712226
Hypoventilation	36.63	15.45	25	25738	7199	79711426
Diarrhoea	36.29	15.45	154	25609	880335	78838290
Laryngospasm	36.10	15.45	20	25743	3977	79714648
Nail dystrophy	35.20	15.45	13	25750	1000	79717625
Loss of personal independence in daily activities	35.14	15.45	92	25671	102488	79616137
Salivary hypersecretion	34.71	15.45	32	25731	14192	79704433
Rales	34.05	15.45	37	25726	19964	79698661
Arthralgia	32.41	15.45	87	25676	571716	79146909
Synovitis	32.35	15.45	5	25758	150729	79567896
Apnoea	31.85	15.45	28	25735	11676	79706949
Sinus tachycardia	30.80	15.45	48	25715	36860	79681765
Angioplasty	30.66	15.45	14	25749	1849	79716776
Body temperature abnormal	30.37	15.45	15	25748	2360	79716265
Arthropathy	29.82	15.45	10	25753	177101	79541524
Seizure	29.45	15.45	130	25633	188704	79529921
Umbilical hernia	29.10	15.45	20	25743	5825	79712800
Pulmonary oedema	29.06	15.45	78	25685	88176	79630449
Restless legs syndrome	28.81	15.45	34	25729	20058	79698567
Axillary pain	28.75	15.45	14	25749	2135	79716490
Pancytopenia	28.54	15.45	9	25754	165736	79552889
Depressed mood	28.53	15.45	54	25709	48426	79670199
Oxygen saturation decreased	28.37	15.45	99	25664	128948	79589677
Blood pressure systolic increased	28.16	15.45	65	25698	66921	79651704
Infective exacerbation of chronic obstructive airways disease	28.11	15.45	15	25748	2769	79715856
Nasal inflammation	27.75	15.45	10	25753	717	79717908
Serotonin syndrome	27.55	15.45	51	25712	44976	79673649
Influenza	27.27	15.45	98	25665	129508	79589117
Blood test abnormal	27.12	15.45	31	25732	17679	79700946
Pulmonary thrombosis	27.05	15.45	26	25737	12145	79706480
Bronchospasm paradoxical	26.99	15.45	7	25756	163	79718462
Eosinophilic granulomatosis with polyangiitis	26.87	15.45	16	25747	3644	79714981
Vulvovaginal candidiasis	26.68	15.45	14	25749	2500	79716125
Off label use	26.58	15.45	178	25585	907037	78811588
Ankle fracture	26.49	15.45	30	25733	16939	79701686
Therapeutic product effect decreased	26.31	15.45	10	25753	163853	79554772
Ischaemic cardiomyopathy	26.30	15.45	21	25742	7674	79710951
Dyslipidaemia	26.14	15.45	25	25738	11608	79707017
Dysphonia	25.93	15.45	57	25706	56815	79661810
Anaphylactic reaction	24.59	15.45	71	25692	83672	79634953
Nasopharyngitis	24.51	15.45	153	25610	253728	79464897
Abdominal discomfort	24.40	15.45	27	25736	250700	79467925
Bronchitis	24.33	15.45	95	25668	130549	79588076
Oedema peripheral	23.71	15.45	151	25612	252137	79466488
Pulmonary congestion	23.67	15.45	36	25727	27064	79691561
Pericarditis	23.44	15.45	3	25760	104233	79614392
Saliva altered	23.38	15.45	8	25755	492	79718133
Depression	23.06	15.45	134	25629	216656	79501969
Increased bronchial secretion	23.01	15.45	14	25749	3313	79715312
Dyspnoea at rest	23.00	15.45	19	25744	7283	79711342
Dyspnoea paroxysmal nocturnal	22.49	15.45	12	25751	2216	79716409
Occupational exposure to air contaminants	22.43	15.45	6	25757	158	79718467
Perfume sensitivity	22.39	15.45	9	25754	870	79717755
Drug hypersensitivity	22.27	15.45	39	25724	298877	79419748
Systemic lupus erythematosus	21.91	15.45	6	25757	121143	79597482
Upper respiratory tract infection	21.85	15.45	72	25691	91096	79627529
Intentional overdose	21.66	15.45	4	25759	105956	79612669
Swelling	21.45	15.45	23	25740	216688	79501937
Anaesthetic complication neurological	21.40	15.45	8	25755	636	79717989
Flank pain	21.19	15.45	29	25734	19815	79698810
Sinus operation	21.08	15.45	12	25751	2513	79716112
Choking sensation	20.96	15.45	14	25749	3892	79714733
White blood cell count decreased	20.95	15.45	18	25745	188270	79530355
Cholelithiasis	20.93	15.45	50	25713	52614	79666011
Staphylococcal scalded skin syndrome	20.86	15.45	7	25756	406	79718219
Intentional product misuse	20.78	15.45	3	25760	95162	79623463
Respiratory symptom	20.62	15.45	15	25748	4776	79713849
Cellulitis	20.49	15.45	5	25758	109055	79609570
Muscle disorder	20.42	15.45	16	25747	5691	79712934
Accelerated idioventricular rhythm	20.25	15.45	6	25757	231	79718394
Cardiorenal syndrome	20.21	15.45	10	25753	1579	79717046
Crepitations	19.67	15.45	20	25743	9997	79708628
Stress cardiomyopathy	19.61	15.45	21	25742	11145	79707480
Haemoglobin decreased	19.41	15.45	26	25737	222093	79496532
Respiratory rate increased	19.30	15.45	29	25734	21571	79697054
Neutropenia	19.28	15.45	40	25723	287670	79430955
Hypopnoea	19.20	15.45	15	25748	5314	79713311
Hypoxia	19.16	15.45	75	25688	103168	79615457
Cerebral thrombosis	19.01	15.45	11	25752	2376	79716249
Acute kidney injury	18.86	15.45	95	25668	519309	79199316
Drug abuse	18.78	15.45	15	25748	162676	79555949
Sputum purulent	18.69	15.45	9	25754	1340	79717285
Bradycardia	18.66	15.45	90	25673	135467	79583158
Blood bilirubin increased	18.34	15.45	55	25708	66177	79652448
Psychotic disorder	18.32	15.45	41	25722	41361	79677264
Upper airway obstruction	18.20	15.45	9	25754	1419	79717206
Platelet count decreased	17.82	15.45	22	25741	194642	79523983
Physical deconditioning	17.72	15.45	10	25753	2060	79716565
Peripheral vascular disorder	17.56	15.45	17	25746	8013	79710612
C-reactive protein increased	17.43	15.45	10	25753	129017	79589608
Aphonia	17.42	15.45	19	25744	10293	79708332
Brain injury	17.36	15.45	20	25743	11497	79707128
Opisthotonus	17.29	15.45	7	25756	689	79717936
Suicide attempt	17.24	15.45	3	25760	82929	79635696
Granulomatosis with polyangiitis	17.14	15.45	11	25752	2859	79715766
Muscle spasms	16.79	15.45	19	25744	174711	79543914
Dystonia	16.71	15.45	27	25736	21372	79697253
Staphylococcus test positive	16.63	15.45	15	25748	6466	79712159
Impaired healing	16.50	15.45	4	25759	87651	79630974
Respiratory acidosis	16.13	15.45	19	25744	11181	79707444
Pain in extremity	16.05	15.45	62	25701	364476	79354149
Heart rate increased	15.79	15.45	79	25684	120645	79597980
Catheter site haemorrhage	15.47	15.45	13	25750	5104	79713521

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A03AB02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Synthetic anticholinergics, quaternary ammonium compounds
ATC	A03CA05	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Synthetic anticholinergic agents in combination with psycholeptics
ATC	D11AA01	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Antihidrotics
ATC	R03AL04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03AL07	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03AL09	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03AL11	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03AL12	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03BB06	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Anticholinergics
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:48876	muscarinic antagonists
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Chronic obstructive lung disease	indication	13645005	DOID:3083
General anesthesia	indication	50697003
Excessive salivation	indication	53827007
Hyperhidrosis of axilla	indication	303089000
Vagal Reflex Bradycardia	indication
Irritable bowel syndrome	off-label use	10743008	DOID:9778
Diarrhea	off-label use	62315008
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Hyperammonemia	contraindication	9360008
Hepatic encephalopathy	contraindication	13920009	DOID:13413
Severe chronic ulcerative colitis	contraindication	14311001
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Poisoning by phenobarbital	contraindication	64921004
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Hepatic coma	contraindication	72836002	DOID:12550
Sleep apnea	contraindication	73430006	DOID:0050847
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hiatal hernia	contraindication	84089009	DOID:12642
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Gastrointestinal obstruction	contraindication	126765001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Dyspnea	contraindication	267036007
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Preanesthesia	Indication
Dogs	Preanesthesia	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Robinul-V Injectable	Zoetis Inc.	1
Glycopyrrolate Injectable, Robinul-V	Cronus Pharma Specialities India Private Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1MG/5ML	CUVPOSA	MERZ PHARMS	N022571	July 28, 2010	RX	SOLUTION	ORAL	7638552	Aug. 20, 2023	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
1MG/5ML	CUVPOSA	MERZ PHARMS	N022571	July 28, 2010	RX	SOLUTION	ORAL	7816396	Aug. 20, 2023	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
15.6MCG/INH;27.5MCG/INH	UTIBRON	NOVARTIS	N207930	Oct. 29, 2015	DISCN	POWDER	INHALATION	6878721	Feb. 25, 2025	LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
25MCG/ML	LONHALA MAGNAIR KIT	SUMITOMO PHARMA AM	N208437	Dec. 5, 2017	DISCN	SOLUTION	INHALATION	10940110	Feb. 26, 2029	LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	10716753	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	8324266	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	8703806	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	8808713	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	9415009	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	9463161	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	10716753	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	8324266	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	8703806	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	8808713	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	9415009	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	9463161	May 28, 2030	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.0048MG/INH;0.0090MG/INH	BEVESPI AEROSPHERE	ASTRAZENECA	N208294	April 25, 2016	RX	AEROSOL, METERED	INHALATION	8815258	March 17, 2031	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	8815258	March 17, 2031	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
25MCG/ML	LONHALA MAGNAIR KIT	SUMITOMO PHARMA AM	N208437	Dec. 5, 2017	DISCN	SOLUTION	INHALATION	10744277	Dec. 7, 2036	A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.16MG/INH;0.0048MG/INH;0.009MG/INH	BREZTRI AEROSPHERE	ASTRAZENECA AB	N212122	July 23, 2020	RX	AEROSOL, METERED	INHALATION	July 23, 2023	NEW COMBINATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9.69	SCIENTIFIC LITERATURE	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	9.25	SCIENTIFIC LITERATURE	IUPHAR
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	9.64	SCIENTIFIC LITERATURE	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Ki	9.06	SCIENTIFIC LITERATURE	IUPHAR
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	ANTAGONIST	Ki	8.91	SCIENTIFIC LITERATURE	IUPHAR

External reference:

ID	Source
4018421	VUID
N0000146747	NUI
D00540	KEGG_DRUG
51186-83-5	SECONDARY_CAS_RN
740028-90-4	SECONDARY_CAS_RN
4018421	VANDF
4038210	VANDF
C4082411	UMLSCUI
CHEBI:90972	CHEBI
CHEMBL1201027	ChEMBL_ID
11693	PUBCHEM_CID
7459	IUPHAR_LIGAND_ID
DB00986	DRUGBANK_ID
1546438	RXNORM
4794	MMSL
609	MMSL
d00992	MMSL
001737	NDDF
017641	NDDF
387122008	SNOMEDCT_US
769097000	SNOMEDCT_US
772943003	SNOMEDCT_US
D006024	MESH_DESCRIPTOR_UI
CHEMBL1201335	ChEMBL_ID
CHEMBL3707243	ChEMBL_ID
1038	INN_ID
V92SO9WP2I	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1250	TABLET	1 mg	ORAL	ANDA	12 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1251	TABLET	2 mg	ORAL	ANDA	12 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9584	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9584	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9585	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9585	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9586	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9586	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9587	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9587	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	23 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9679	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9679	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9680	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9680	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9681	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9681	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9682	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9682	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	24 sections
Cuvposa	HUMAN PRESCRIPTION DRUG LABEL	1	0259-0501	LIQUID	1 mg	ORAL	NDA	27 sections
Glycopyrrolate	HUMAN PRESCRIPTION DRUG LABEL	1	0259-0502	LIQUID	1 mg	ORAL	NDA AUTHORIZED GENERIC	30 sections
BEVESPI AEROSPHERE	HUMAN PRESCRIPTION DRUG LABEL	2	0310-4600	AEROSOL, METERED	9 ug	RESPIRATORY (INHALATION)	NDA	29 sections
BEVESPI AEROSPHERE	HUMAN PRESCRIPTION DRUG LABEL	2	0310-4600	AEROSOL, METERED	9 ug	RESPIRATORY (INHALATION)	NDA	29 sections
BEVESPI AEROSPHERE	HUMAN PRESCRIPTION DRUG LABEL	2	0310-4600	AEROSOL, METERED	9 ug	RESPIRATORY (INHALATION)	NDA	29 sections
BREZTRI	HUMAN PRESCRIPTION DRUG LABEL	3	0310-4616	AEROSOL, METERED	9 ug	RESPIRATORY (INHALATION)	NDA	28 sections
BREZTRI	HUMAN PRESCRIPTION DRUG LABEL	3	0310-4616	AEROSOL, METERED	9 ug	RESPIRATORY (INHALATION)	NDA	28 sections
GLYCOPYRROLATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9867	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	12 sections
GLYCOPYRROLATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9867	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	12 sections
GLYCOPYRROLATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9868	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	12 sections
GLYCOPYRROLATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9868	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	12 sections
GLYCOPYRROLATE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9869	INJECTION	0.20 mg	INTRAMUSCULAR	ANDA	12 sections